NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare ...
The FDA has received a new application for Anktiva plus BCG to treat BCG-unresponsive non–muscle invasive bladder cancer with ...
Boston Consulting Group (BCG) and OpenAI today announced a multiyear expansion of their partnership with Frontier Alliance to continue to help organizations move beyond experimentation and accelerate ...
The FDA has acknowledged receipt of the supplemental Biologics License Application (sBLA) for nogapendekin alfa inbakicept-pmln (Anktiva) plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive ...
OpenAI’s new Frontier Alliances with Accenture, BCG, Capgemini, and McKinsey aim to speed enterprise agent deployments and AI strategy work.
Intravesical BCG is the standard of care (SOC) for BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC) patients.
The Chosun Ilbo on MSN
GM redefines marketing strategy with AI-driven demand focus
The most frequent question heard in consulting settings these days is, “How much can artificial intelligence (AI) improve marketing efficiency?” Many companies focus on using AI to produce images and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results